Lytix Biopharma AS
OSL: LYTIX.OL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Oslo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Oystein Rekdal
- Employees
- 6
- Headquarters
- Oslo, Norway
- IPO year
- 2021
- Market cap
- NOK 681.7M
- Website
- https://www.lytixbiopharma.com
Loading LYTIX…
Loading profile data…Frequently asked questions about LYTIX
What does Lytix Biopharma AS (LYTIX.OL) do?
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comp...
Where does LYTIX.OL trade?
Lytix Biopharma AS (LYTIX.OL) trades on the Oslo Stock Exchange.
What sector is LYTIX.OL in?
Lytix Biopharma AS (LYTIX.OL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lytix Biopharma AS?
Oystein Rekdal is the chief executive officer of Lytix Biopharma AS (LYTIX.OL).
Where is Lytix Biopharma AS headquartered?
Lytix Biopharma AS is headquartered in Norway.
Does LYTIX.OL pay a dividend?
Lytix Biopharma AS (LYTIX.OL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LYTIX.OL go public?
Lytix Biopharma AS (LYTIX.OL) completed its initial public offering in 2021.